Phase II study of tiazofurin (NSC 286193) in the treatment of advanced small cell bronchogenic carcinoma.
作者信息
Holoye P Y, Carr D T, Dhingra H M, Glisson B S, Lee J S, Murphy W K, Umsawasdi T, Jeffries D
机构信息
Department of Medical Oncology, University of Texas M.D. Anderson Hospital and Tumor Institute, Houston 77030.
出版信息
Invest New Drugs. 1988 Sep;6(3):217-8. doi: 10.1007/BF00175401.
PMID:2847992
Abstract
Fourteen evaluable patients with small cell bronchogenic carcinoma received tiazofurin, an inhibitor of inosine monophosphate dehydrogenase, that progressed after one combination chemotherapy. No objective remission was observed at the dosage of 800 mg/m2 for 5 consecutive days. Toxicity was moderate.
摘要
Zotero 插件